Acrivon Therapeutics (ACRV) Other Non Operating Income (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Other Non Operating Income of -$129000.0 for Q1 2026, down 821.43% year-over-year from $17881.2 in Q1 2025, and down 11.21% quarter-over-quarter from -$116000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Other Non Operating Income (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Other Non Operating Income for 6 consecutive years, with -$129000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 821.43% year-over-year to -$129000.0; the TTM figure through Mar 2026 stood at -$385000.0 (down 25.0% YoY), while the FY2025 annual figure was -$270000.0, up 51.61% from the prior year.
- Other Non Operating Income slipped to -$129000.0 in Q1 2026 per ACRV's latest filing, from -$116000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.0 million in Q4 2022 and bottomed at -$264000.0 in Q1 2024.
- Historically, Other Non Operating Income has averaged $12411.8 across 5 years, with a median of -$55000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 12666.67% — and 2025, when it sank 5400.0%.
- Acrivon Therapeutics' Other Non Operating Income stood at $1.0 million in 2022, then slumped by 89.27% to $109000.0 in 2023, then slumped by 320.18% to -$240000.0 in 2024, then soared by 51.67% to -$116000.0 in 2025, then fell by 11.21% to -$129000.0 in 2026.
- Business Quant data shows ACRV's Other Non Operating Income at -$129000.0 in Q1 2026, -$116000.0 in Q4 2025, and -$53000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -156,000.00 |
| Mar 31, 2026 | -129,000.00 |
| Dec 31, 2025 | -116,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Jun 30, 2025 | -87,000.00 |
| Mar 31, 2025 | -14,000.00 |
| Dec 31, 2024 | -240,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | -55,000.00 |
| Mar 31, 2024 | -264,000.00 |
| Dec 31, 2023 | 109,000.00 |
| Sep 30, 2023 | -97,000.00 |
| Jun 30, 2023 | -164,000.00 |
| Mar 31, 2023 | -170,000.00 |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 377,000.00 |
| Jun 30, 2022 | 105,000.00 |
| Mar 31, 2022 | -8,000.00 |
| Dec 31, 2021 | -17,000.00 |
| Sep 30, 2021 | -3,000.00 |